Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse split is aimed at regaining compliance with Nasdaq listing requirements.
The Company expects its common stock to trade on a split-adjusted basis starting August 18, 2025.
Reverse Stock Split
Company plans 1 for 3 reverse stock split to meet Nasdaq listing rule compliance.
Board Approval
Reverse stock split approved by the Board of Directors and shareholders.
Reduced Shares
Outstanding common stock to decrease from 4.77 million to approximately 1.59 million shares.
No Fractional Shares
Stockholders will receive cash instead of fractional shares after the split.
CEO Statement
Interim CEO Richard Paolone emphasizes the importance of maintaining Nasdaq listing.
- The reverse stock split will improve visibility and credibility of the company on the Nasdaq market.
- Reducing outstanding shares may positively impact shareholder value and market perception.
The reverse stock split signals Entero Therapeutics' commitment to compliance and enhancing shareholder value in the market.